Psoralane Ultraviolet A (PUVA) therapy is advised in__________?
A. Pemphigus vulgaris
B. Apthous ulcers
C. Carcinoma in situ
D. ANUG
A. Pemphigus vulgaris
B. Apthous ulcers
C. Carcinoma in situ
D. ANUG
A. Oral hairy leukoplakia
B. Aspirin burn
C. White spongy nevus
D. Pseudomembranous Candidiasis
A. Etiological agents differ
B. The acute form occurs only inversely immuno compromised individuals
C. The primary infection was subclinical
D. The patient has received antibodies during intrauterine life and the antibodies have persisted
A. Ankylosis
B. Synovial chondromatosis
C. Subluxation
D. Osteorthritis
A. Equal lengths of base paste and accelerator paste are mixed together until the mix has a uniform colour
B. Increase in temperature and humidity shorten the setting time
C. The mix appear thick at the start of mixing but after 30 seconds of additional spatulation it becomes more fluid
D. Water accelerates but heat retards the setting of zinc oxide eugenol cements
E. Both C & D
A. 1 ml / min
B. 2.5 ml / min
C. 1 mg / min
D. 2.5 mg / min
A. Type I
B. Type III
C. Type II
D. Type IIII and I